Testosterone Replacement Therapy
Restoration of testosterone levels to optimal physiological range in men with hypogonadism or age-related decline.
Evidence Summary
The landmark TRAVERSE trial (Lincoff et al., NEJM 2023; 5,246 men aged 45–80 randomized, 5,204 in the full-analysis set, with symptomatic hypogonadism and elevated cardiovascular risk, mean follow-up 33 months) established cardiovascular non-inferiority: major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% of placebo (hazard ratio 0.96, 95% CI 0.78–1.17). On the strength of these data, in February 2025 the U.S. FDA removed the long-standing boxed ("black-box") cardiovascular warning from all testosterone products, concluding that testosterone does not increase the risk of major adverse cardiac events when used for documented hypogonadism. Prespecified secondary analyses still showed modestly higher rates of atrial fibrillation (3.5% vs 2.4%, P=0.02), venous thromboembolism, and acute kidney injury in the testosterone group. A dedicated fracture sub-study (Snyder et al., NEJM 2024) unexpectedly found more clinical fractures with testosterone (3.50% vs 2.46%; hazard ratio 1.43, 95% CI 1.04–1.97), so testosterone should not be used to prevent fractures. 2024–2026 systematic reviews and position statements continue to concur: in properly selected, symptomatic hypogonadal men, testosterone therapy has a reassuring cardiovascular profile alongside meaningful benefits for body composition, sexual function, mood, and bone density — provided hematocrit, PSA, blood pressure, and cardiac rhythm are monitored. This is educational information, not medical advice.
Evidence Scale
Mechanism of Action
Exogenous testosterone binds androgen receptors, restoring anabolic signaling, supporting muscle protein synthesis, bone density, erythropoiesis, and CNS function.
Who Is This For?
Symptomatic hypogonadism, documented low testosterone, absence of contraindications. PSA and hematocrit baseline required.
Protocol & Dosing
Dose
Cypionate: 100-200mg/week. Gels: 50-100mg daily. Target total T 700-1000 ng/dL.
Frequency
Weekly injections or daily topicals
Duration
Ongoing with monitoring
Protocol Summary
Various delivery methods: injections (cypionate/enanthate), gels, pellets, patches. Monitoring essential.
Latest Evidence
TRAVERSE trial (2023–2024) + 2025 FDA update
TRAVERSE was a randomized, double-blind, placebo-controlled cardiovascular safety trial of 5,246 men aged 45–80 (5,204 in the full-analysis set) with symptomatic hypogonadism and elevated cardiovascular risk, followed for a mean of ~33 months. Testosterone was non-inferior to placebo for major adverse cardiac events (7.0% vs 7.3%; hazard ratio 0.96, 95% CI 0.78–1.17), resolving a long-standing safety question — and in February 2025 the U.S. FDA removed the long-standing boxed ('black-box') cardiovascular warning from all testosterone products on the strength of these data. Prespecified secondary analyses still showed higher rates of atrial fibrillation (3.5% vs 2.4%), venous thromboembolism, and acute kidney injury with testosterone, and a dedicated fracture sub-study found more clinical fractures with testosterone (3.50% vs 2.46%; hazard ratio 1.43), so it should not be used to prevent fractures.
These findings apply to men with documented hypogonadism under medical supervision. Testosterone should not be used to prevent fractures. Therapy requires monitoring of hematocrit, PSA, and cardiac rhythm. This is educational information, not medical advice.
Human RCT Safety Data · TRAVERSE
Event rates over ~33 months: testosterone vs placebo
5,246 hypogonadal men aged 45–80 with high cardiovascular risk (5,204 analysed). Testosterone was non-inferior to placebo for major adverse cardiac events (MACE) — the basis for the FDA removing testosterone's cardiovascular black-box warning in February 2025 — but showed modestly higher rates of atrial fibrillation, venous thromboembolism (VTE), and clinical fracture, signals that warrant monitoring. Sources: TRAVERSE, Lincoff et al., NEJM 2023 (NEJMoa2215025); fracture sub-study Snyder et al., NEJM 2024 (NEJMoa2308836).
Related on Peak Human
Hormone Optimization
Physician-guided hormone balancing at Peak Human.
Optimization Service
Biomarker-tracked optimization protocols.
Growth Hormone Therapy
A related hormone intervention in the database.
DHEA Supplementation
Adrenal androgen precursor support.
Peptide Therapy
Complementary signaling interventions.
Longevity Research Insider
Weekly review of new longevity research.
How Effective Is hCG at Raising Testosterone?
Evidence review on preserving testicular function and fertility.
Shop: Hormone Support
Physician-vetted hormone-support products.
Interactions & Precautions
Contraindications
- Prostate cancer
- Breast cancer
- Polycythemia
- Untreated sleep apnea
- Fertility goals (relative)
Potential Risks
- •Fertility suppression
- •Cardiovascular effects (disputed)
- •Prostate concerns
- •Dependency
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Optimize estradiol management with an aromatase inhibitor only if clinically indicated. Consider HCG to maintain testicular function and fertility. Monitor hematocrit, PSA, blood pressure, and cardiac rhythm regularly. In light of TRAVERSE (NEJM 2023–2024): screen for and monitor atrial fibrillation and venous thromboembolism risk, and do not prescribe testosterone for fracture prevention — the fracture sub-study showed increased fracture incidence. In February 2025 the FDA removed the boxed cardiovascular warning from testosterone products on the basis of TRAVERSE. Reserve therapy for symptomatic, biochemically confirmed hypogonadism.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
